MedTrace Logo

Diagnosis of Mycoplasma Pneumoniae Infection With Detection of Specific Antibody-secreting Cells in Community-acquired Pneumonia (CAP) Patients of the Randomised Placebo-controlled Multi-centre Effectiveness Trial of Adjunct Betamethasone Therapy

NCT04043325 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2020-11-13

No results posted yet for this study

Summary

To compare presence and kinetics of Mycoplasma pneumoniae (Mp)-specific immunoglobulin (Ig) M antibody-secreting cells (ASCs) with Mp DNA and Mp-specific IgM antibodies in patients with community-acquired pneumonia (CAP) of the KIDS-STEP study.

Conditions

  • Community-acquired Pneumonia

Interventions

DIAGNOSTIC_TEST

Specific antibody-secreting cell (ASC) enzyme-linked immunspot (ELISpot) assay

Clinical samples (nasopharyngeal swabs and max. 5 ml blood) will be collected from patients enroled in the KIDS-STEP study (NCT03474991; children aged 1-10 years) at enrolment (day 1), at day 3, and at day 28.

Sponsors & Collaborators

  • University Children's Hospital Basel

    collaborator OTHER

  • Ostschweizer Kinderspital

    collaborator OTHER

  • University Children's Hospital, Zurich

    lead OTHER

Eligibility

Min Age
1 Year
Max Age
10 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-20
Primary Completion
2021-12-31
Completion
2021-12-31

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04043325 on ClinicalTrials.gov